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Abstract:  Ribosome-inactivating  proteins  (RIPs)  are  a  family  of  plant  toxins  that 
permanently damage ribosomes and possibly other cellular substrates, thus causing cell 
death. RIPs are mostly divided in two types: Type 1 RIPs that are single-chain enzymatic 
proteins, and type 2 RIPs that consist of an active A chain (similar to a type 1 RIP) linked 
to a B chain with lectin properties. RIP-containing conjugates have been used in many 
experimental strategies against cancer cells, often showing great efficacy in clinical trials. 
Saporin-S6,  a  type  1  RIP  extracted  from  Saponaria  officinalis  L.  seeds,  has  been 
extensively  utilized  to  construct  anti-cancer  conjugates  because  of  its  high  enzymatic 
activity, stability and resistance to conjugation procedures, resulting in the efficient killing 
of  target  cells.  This  review  summarizes  saporin-S6-containing  conjugates  and  their 
application  in  cancer  therapy,  considering  in-vitro  and  in-vivo  studies  both  in  animal 
models  and in  clinical  trials. The review is  structured on the basis of the targeting of 
hematological versus solid tumors and on the antigen recognized on the cell surface. 
Keywords: saporin-S6; plant toxins; immunotoxins; immunoconjugates; immunotherapy; 
anti-cancer therapy 
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1. Introduction  
Ribosome-inactivating proteins (RIPs) are plant enzymes that damage ribosomes, and possibly other 
substrates, in an irreversible manner. RIPs are mainly divided into type 1, which consist of a single-chain 
protein, and type 2, which are composed of an enzymatic A-chain linked to a B-chain possessing lectin 
properties [1]. The interest in RIPs derives mostly from potential applications after being linked to 
appropriate carriers, such as monoclonal antibodies (mAbs) or other molecules, to obtain conjugates that 
are specifically toxic to target cells [2]. These conjugates have been included in experimental therapies 
against various malignancies, often achieving promising results. Among type 1 RIPs, Saporin-S6 (SAP; 
from seeds of Saponaria officinalis L. [3]) has been widely used to construct anti-cancer conjugates 
because of its high enzymatic activity [4] that has been related to the negative electrostatic surface 
potential  of  the  active  site  pocket  [5].  Further  positive  aspects  of  SAP  are  the  maintenance  of  its 
enzymatic activity after conjugation procedures [6] and its resistance to proteolytic degradation, thus 
producing very efficient conjugates for the killing of target cells [7]. 
This review summarizes the applications of SAP-containing conjugates in experimental therapies 
against hematological and solid tumors, considering in-vitro and in-vivo studies both in animal models 
and in clinical trials. Conjugates containing antibodies or their fragments are referred to as immunotoxins 
(ITs), whereas conjugates having other carriers are denoted as “conjugates”. Unless otherwise specified, 
the conjugates and the ITs listed in this review have been obtained by chemical conjugation. 
2. ITs Targeting Hematological Cells  
Hematological cells have been extensively studied and targeted with  ITs because (i) they have  
well-known and well-characterized surface molecules against which a panel of mAbs is available;  
(ii) many surface antigens modulate and are effectively internalized after binding with specific Abs; 
(iii) fresh cells may be easily tested for IT activity; and (iv) hematological neoplastic cells are easier to 
access and target in vivo compared to solid tumor cells. The main results obtained in vitro and in 
animal models are summarized in Table 1. Clinical trials are reported in Table 2. 
Table 1. In vitro and in vivo studies with Saporin-S6 (SAP) containing immunotoxins (ITs) 
targeting hematological tumors. 
  Antitumor Activity   
Antibody 
Target 
Antigen 
Tumor  In vitro IC50 (M) 
In vivo 
Ref. 
Schedule  Effects 
Various  CD2  T-CLL  10
−13~10
−11  n.d.  n.d.  [8] 
OKT11 
7A10C9 
CD2  T-CLL  <5 ×  10
−13  n.d.  n.d.  [9] 
OKT1  CD5 
T-lymphocytes 
B-CLL 
3.2 ×  10
−10; 
4~6.8 ×  10
−9 
n.d.  n.d.  [10,11] 
UCHT1  CD3  lymphocytes  2.1 ×  10
−10  n.d.  n.d.  [6,12] 
HB2 ×  DB7-18  CD7  T-ALL  2.3 ×  10
−10  n.d.  n.d.  [13,14] 
HB2  CD7  T-ALL  4.5 ×  10
−12 
SCID-HSB2 mice; 
1 ×  0.5 mg/kg 
50% survival  
at 150 days 
[15,16] Toxins 2011, 3                               
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Table 1. Cont. 
  Antitumor Activity   
Antibody 
Target 
Antigen 
Tumor  In vitro IC50 (M) 
In vivo 
Ref. 
Schedule  Effects 
BU12  CD19 
B-LL   
SCID-NALM-6 mice;  
3 ￗ 10 μg 
40% survival  
at 110 days 
[17] 
BL   
SCID-Ramos mice;  
1 ￗ 10 μg IT + 10 μg 
Rituximab 
100% survival  
at 120 days 
[18,19] 
Rituximab  CD20  NHL  1~3 ×  10
−10  n.d.  n.d.  [20] 
F(ab’)2 BsAbs  CD22  BL  1.5~6 × 10
−10  n.d.  n.d.  [21] 
OM124  CD22 
B lymphoblastoid, 
BL 
<5 × 10
−15~2.0 × 
10
−11 
SCID-Daudi mice 
3 × 0.5 mg/kg 
2 × 0.5 mg/Kg IT + 60 
mg/Kg 
cyclophosphamide 
33% tumor free 
66% tumor free 
[22] 
Ber-H2  CD30 
HD  5 × 10
−12~5 × 10
−14  n.d.  n.d.  [23] 
ALCL   
SCID-JB6 mice 
3 ￗ 11.3 μg 
CR 80% 
CR 30% 
[24] 
ALCL   
SCID-D430B mice 
1 ×  0.1 mg/kg 
CR 66% 
PR 33% 
[25] 
IB4  CD38  NHL  2~13 ×  10
−12  n.d.  n.d.  [26] 
B7-24  CD80  BL, HD  <10
−11  n.d.  n.d.  [27] 
M24 + IG10 
CD80/ 
CD86 
BL, HD  0.3~5.8 × 10
−12  n.d.  n.d.  [28] 
83 
CD3/ 
CD28 
lymphocytes 
8 × 10
−11 
AC50 2 × 10
−12 
n.d.  n.d.  [29] 
ALL  AC50 10
−11  n.d.  n.d.  [30] 
ATG  various 
lymphoma and 
leukemia cells 
5 × 10
−11~10
−10  n.d.  n.d.  [31] 
ALCL: anaplastic large-cell lymphoma; ALL: acute lymphoblastic leukemia; B-CLL; B-chronic lymphocytic 
leukemia;  BL:  Burkitt’s  lymphoma;  B-LL:  B-cell  lymphoblastic  leukemia;  CR:  complete  remission;  
HD:  Hodgkin’s  disease;  NHL:  non-Hodgkin’s  lymphoma;  PR:  partial  remission;  n.d.:  not  determined;  
T-ALL: T-cell acute lymphoblastic leukemia; T-CLL: T-cell chronic lymphocytic lymphoma. 
Table 2. Clinical trials in patients with SAP containing ITs. 
Antibody  Antigen  Disease  Total Dose  PR  SD/MR  No. patients  Ref. 
F(ab’)2 BsAb  CD22  NHL  5 mg  -  1  1  [32] 
4KB128 + HD6  CD22 
B-cell 
lymphoma 
5–20 mg  -  4  4  [33] 
F(ab’)2 BsAb  CD22  NHL  5–20 mg  -  5  5  [34] 
Ber-H2  CD30  HD  0.8 mg/kg  3 (75%)  1 (25%)  4  [35] 
Ber-H2  CD30  HD  0.2–0.8 mg/kg  5 (40%)  3 (25%)  12  [36] 
HD:  Hodgkin’s  disease;  NHL:  non-Hodgkin’s  lymphoma;  PR:  partial  remission;  SD/MR:  stable 
disease/minor response. Toxins 2011, 3                               
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2.1. ITs Targeting CD2, CD3 and CD5 
SAP was used to prepare several ITs with mAbs against CD2, CD3 and CD5. CD2 is a 50 kDa 
glycoprotein expressed on the surface of T cells, natural killer (NK) cells, granulocytes and on subsets 
of monocytes and B cells. Anti-CD2 ITs have been studied as therapies for CD2
+ lymphomas and 
leukemias.  Various  anti-CD2  mAbs  (GT2,  OKT11,  8E5B3,  8G5B12,  7A10C9)  were  used  by  
Tazzari  et  al. [8] to produce SAP-containing  ITs.  These conjugates were found to  inhibit protein 
synthesis  in  a  neoplastic  CD2
+  cell  line  (SKW-3)  and  in  an  IL-2-dependent  CD2
+  lymphoid  cell 
culture  (T  lymphoblasts)  with  concentrations  causing  50%  of  protein  synthesis  inhibition  (IC50s) 
ranging  from  10
−13  to  10
−11  M.  The  most  effective  ITs,  OKT11-  and  7A10C9-SAP,  were  further 
investigated in D430B cells (anaplastic large-cell lymphoma), with IC50s lower than 5 ×  10
−13 M. Bone 
marrow purging of contaminating lymphoma cells by means of CD34
+ cell purification and subsequent 
OKT11-SAP treatment resulted in >5 logs of lymphoma cell killing without any significant reduction 
in stem cell clonogenic properties [9]. 
CD5 (gp67) is a developmental marker of T lymphocytes that is also present on the surface of  
B cell subsets. Anti-CD5 ITs have been devised as a tool for the therapy of T-cell lymphomas and 
leukemias and CD5
+ B-chronic lymphocytic leukemia (B-CLL). The OKT1-SAP IT showed very fast 
kinetics.  Indeed, T-lymphocyte killing  was  achieved with  only 5 min  of exposure to  the  IT.  The 
concentration causing 50% of inhibition of T-lymphocyte DNA synthesis was 3.2 ×  10
−10 M. This IT 
was given as a single intravenous (i.v.) injection at non-toxic dosages (0.16–1.3 mg/kg) in cynomolgus 
monkeys.  An  initial  rapid  decline  in  plasma  concentration  (t1/2α  =  1.0–4.1  h)  was  followed  by  a  
long-lasting slower decrease (t1/2β = 11.6–20.6 h) [10]. This IT was also tested on fresh B-CLL cells 
from 31 patients. In 90% of cases, OKT1-SAP specifically suppressed B-CLL cell proliferation in a  
dose-related manner, with IC50s 4.0–6.8 ×  10
−9 M [11]. 
In a comparative study, different CD antigens were targeted by specific mAbs [OKT11 (anti-CD2), 
SOT3 (anti-CD3) and SOT1a (anti-CD5)] linked to SAP. The anti-CD2 IT OKT11-SAP was 10-fold less 
effective than the other two ITs. However, OKT11-SAP, similarly to SOT3- and SOT1a-containing ITs, 
was able to accomplish T lymphocyte killing after less than 10 min of exposure in the absence of 
adjuvant molecules [37]. 
An IT containing the anti-CD3 mAb UCHT1 linked to SAP showed cytotoxic effects on stimulated 
human peripheral lymphocytes. The IT showed an IC50 of 2.1 ×  10
−10 M with a 2 log increase in SAP 
toxicity [6,12]. 
2.2. ITs Targeting CD7 
CD7 is a 40 kDa determinant expressed by most T-cell acute lymphoblastic leukemias (T-ALLs) 
and the majority of normal mature peripheral T cells. HB2 has been one of the most used mAbs to 
produce anti-CD7 ITs. SAP was effectively delivered to the T-ALL cell line HSB-2 by a F(ab’γ)2 
bispecific antibody (BsAb) specific for SAP and CD7 antigen. The IT showed an IC50 of 2.3 ×  10
−10 M 
and a rate of protein synthesis inactivation very similar to that described for conventional ITs (time 
taken for a one log inhibition of protein synthesis compared with controls (t10) of 46 h at 10
−9 M and 
226 h at 10
−10 M) [13]. The cytotoxic performance of an HB2-derived BsAb, also reacting with SAP 
(HB2 ×  DB7-18), was investigated in vitro. With HSB-2 cells the HB2 ×  DB7-18 BsAb had an IC50 of Toxins 2011, 3                               
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2.3 ×  10
−10 M with a 435-fold increase in SAP toxicity [14]. Comparative experiments showed that the 
HB2-SAP IT was six times more effective than HB2 ×  DB7-18 and 98 times more effective than the 
corresponding quadroma BsAb Q1.1 [38]. An HB2-SAP IT was found to specifically inhibit HSB-2 
cell line protein synthesis with an IC50 of 4.5 ×  10
−12 M and it significantly prolonged the survival of 
several combined immunodeficient (SCID) mice injected with HSB-2 cells. This therapeutic effect 
was seen with a single injection of 10 µg (0.5 mg/kg) of IT given at day +7 [15], and it was even more 
evident when the IT was administered as three daily injections of 10 µg on days +7, +8 and +9 [16]. 
Further  experiments  revealed  that  host-mediated  antibody  dependent  cell  cytotoxicity  (ADCC) 
contributes to the in vivo therapeutic efficacy of HB2-SAP IT, as demonstrated by both the reduced 
activity of an IT constructed with the HB2 F(ab’)2 fragment, which is incapable of recruiting NK  
cells
 [39], and the reduced activity of HB2-SAP in NOD/SCID mice, which have reduced cytolytic NK 
activity
 [40]. In vivo assessments of the same IT constructed with either a hindered (HB2-SMPT-SAP) 
or non-hindered (HB2-SPDP-SAP) disulphide bond
 [41], and containing one or two SAP moieties
 [42], 
failed to reveal significant differences in pharmacokinetic [41] or therapeutic effects [41,42]. 
2.3. ITs Targeting CD19 
CD19  is  a  95  kDa  glycoprotein  that  functions  as  a  response  regulator  that  modulates  B-cell 
differentiation. It is expressed on the B lymphocyte lineage from the beginning of B-cell commitment 
to plasma cell differentiation, and it is also present on B-cell lymphomas and leukemias. HD37 mAb 
conjugated to SAP is an IT found to kill more than 2 logs of clonogenic B-CLL cells from patients 
after a 2 h incubation at a concentration not toxic to non-target cells
 [43]. 
The BU12-SAP IT was constructed by covalent coupling of SAP to the BU12 mAb. This IT is 
selectively cytotoxic in vitro in a dose-dependent manner for the CD19
+ B-cell acute lymphoblastic 
leukemia cell line NALM-6, but it exhibits no toxicity for the CD19
− T-ALL cell line HSB-2. The 
survival of SCID mice challenged with NALM-6 cells was significantly prolonged compared with 
sham-treated control animals by a course of therapy with 3 ×  10 μg doses of BU12-SAP but not with 
an irrelevant anti-CD7 IT
 [17]. Similar results were obtained with SCID mice challenged with the 
CD19
+ human Burkitt’s lymphoma cell line Ramos treated with 3 doses of BU12-SAP IT starting at 
day + 7 from tumor cell injection
 [18]. Flavell et al. explored the augmentative effect of Rituximab on 
BU12-SAP in a model of human lymphoma. A combination of 10 μg Rituximab + 10 μg BU12-SAP 
completely abolished Ramos cell proliferation in vitro and induced a significantly greater degree of 
apoptosis. In SCID-Ramos mice, treatment with a mixture of 10 μg Rituximab + 10 μg BU12-SAP 
starting at day +7 from i.v. injection of tumor cells had a better therapeutic effect than the individual 
agents. Indeed, the IT used individually significantly prolonged survival (maximal survival time from 
35 to 75 days), but all animals succumbed by day 75. When the IT and Rituximab were used in 
combination, all animals survived and were disease free at day +120. The therapeutic efficacy was 
reduced in SCID-Ramos mice depleted of serum complement, whereas NK cell depletion failed to 
show any convincing role for ADCC [19]. Toxins 2011, 3                               
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2.4. ITs Targeting CD20 
The  CD20  antigen,  a  33–37  kDa  membrane  protein  of  unknown  function,  is  an  excellent 
immunotherapeutic target as it is expressed only on mature B cells and not on B-cell precursors. The 
chimaeric mAb Rituximab has emerged as an effective single agent for the treatment of patients with 
CD20
+ non-Hodgkin’s lymphoma (NHL) or chronic lymphocytic leukemia (CLL). In 1997, Rituximab 
was approved by the US FDA for the treatment of recurrent/refractory follicular NHL and of untreated 
aggressive NHL in combination with the cyclophosphamide-hydroxydaunorubicin-oncovin-prednisone 
(CHOP) regimen. Rituximab treatment showed a response rate of about 50% in relapsed low-grade  
NHL [44]. A Rituximab-SAP IT was constructed and tested in vitro for its anticancer properties. Upon 
conjugation,  the  toxicity  of  SAP  for  target  cells  increased  by  about  3  logs,  with  IC50  values  of  
1–3 ×  10
−10 M. The percentage of AnnexinV
+ cells was over 95% in cell lines treated with 10
−8 M IT. 
The complete elimination of Raji clones was achieved with 10
−8 M IT, whereas a mixture of free RIP 
and mAb gave about 90% clonogenic growth. Rituximab-SAP was also found to induce apoptosis in 
80% of lymphoma cells from NHL patients. Moreover, Raji sensitivity to the IT was augmented when 
cells  were  coincubated  with  Fludarabine,  one  of  the  most  widely  used  chemotherapy  drugs.  The 
synergistic toxic effect of these two drugs led to the total elimination of the neoplastic population [20]. 
2.5. ITs Targeting CD22 
CD22 is a 135 kDa B-cell restricted sialoglycoprotein that has a role as a component of the B-cell 
activation complex and as an adhesion molecule. CD22 is expressed on the surface of B-cells only at 
mature stages of differentiation, and it is also expressed by the majority of B-cell malignancies. SAP 
was  found  to  be  effectively  delivered  to  malignant  B-cells  by  four  different  anti-CD22/anti-SAP 
F(ab’)2 BsAbs. Each α-CD22 BsAb increased SAP toxicity up to 1000-fold, reaching IC50 values of 
1.5–6.0 ×  10
−10 M for both Daudi and Raji target cells. Pairs of anti-CD22 BsAbs that recognize 
different non-blocking epitopes on the SAP molecule are able to bind SAP more tightly to the target 
cell and, as a consequence, increase SAP cytotoxicity and lower the IC50 to 2 ×  10
−11 M [21]. 
In a  clinical  trial, F(ab’)2  BsAb was  used to  deliver SAP  in  the treatment  of one patient  with  
end-stage NHL. Giving 5 mg of SAP complexed with a pair (50 mg) of anti-CD22 BsAbs over 15 days 
provided a marked clinical response, including complete clearance of tumor from the blood, clearance 
of ascites and shrinkage of tumor masses. The patient developed a strong anti-mouse Fab response  
28 days after the start of treatment. No anti-SAP response was detected [32]. Four patients were treated 
with two BsAbs directed to different epitopes of CD22 (4KB128 and HD6) and SAP as therapy for 
low grade end-stage B-cell lymphoma. The patients received between 3 and 6 doses of IT at weekly 
intervals  with  infusions  containing  escalating  doses  of  the  complexes  (ranging  between  
1 and 4 mg) given every hour. Toxic effects were minimal (grade I), with mild fever, weakness and 
myalgia for 1–2 days after the treatment. One patient had an antibody response to mouse Fab’ and 
SAP. All patients showed rapid and beneficial responses to the treatment. In the week after their last 
treatment, all showed at least a 50% reduction in measurable disease, although no response persisted 
for the 28 days defined as being necessary for a partial response. Circulating tumor cells were cleared 
in the three patients with blood involvement. Ascitic fluid and pleural effusions disappeared. Lymph 
nodes showed reductions in size of at least 50% in three patients. One patient had complete resolution Toxins 2011, 3                               
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of severe neutropenia and one lost his transfusion requirement [33]. French et al. treated five low grade 
NHL patients with a cocktail of two BsAbs, which bind cooperatively to SAP, and CD22 on B cells. 
Patients were treated with weekly doses of the IT (3 or 6 infusions between 2 and 4 mg) for a period of 
up to 6 weeks. All weekly treatments were well tolerated and all five patients showed marked clinical 
responses, with removal of the bulk of their disease following treatment. The tumor was removed from 
circulation  (4/5), ascitic fluid and pleural effusions were eradicated (2/2), splenomegaly (1/1) and 
enlarged lymph nodes (5/5) were shrunk, and marrow was partially cleaned, resulting in significant 
improvements in function in some patients. Most of these beneficial effects were achieved rapidly, 
after just three treatments, but in all cases, the duration of the response was short (2–4 weeks) [34]. 
SAP has also been linked to the α-CD22 mAb OM124. This IT is probably the most effective at 
inhibiting protein synthesis in various CD22
+ target cell lines (Daudi, EHM, BJAB, Raji and BM21), 
with IC50s ranging from <5 ×  10
−15 (on EHM cells) to 2 ×  10
−11, and IC90s ranging from 5 ×  10
−14 to 
10
−10 M. Treatment with the IT (0.5 mg/kg at days +1, +4 and +7 after tumor challenge) was found to 
significantly extend the survival time of SCID mice bearing transplanted Daudi cells, with 33% of all 
animals  tumor-free  after  220  days.  The  combination  of  cyclophosphamide  (60  mg/kg  at  days  
+1 and +2) and OM124-SAP (as above) augmented the efficacy so that 66% of the animals remained 
tumor-free after 220 days [22]. The humanized anti-CD22 mAb Epratuzumab conjugated to SAP is 
specifically cytotoxic to CD22
+ lymphoma cell lines, being able to completely eliminate target cells 
while sparing non-target cells. Its cytotoxic effect was demonstrated in vitro by the complete loss of 
viability, and this was found to be related to the complete inhibition of protein synthesis and strong 
induction  of  apoptosis.  This  IT  completely  abolished  the  clonogenic  growth  of  both  BJAB  and  
Raji cells [45]. 
2.6. ITs Targeting CD30 
CD30 is a member of the TNF receptor family. It was originally described as a marker of Hodgkin 
and  Reed-Sternberg  cells  in  Hodgkin’s  lymphoma.  CD30  expression  is  mostly  restricted  to  
virus-infected  lymphocytes,  neoplasms  of  lymphoid  origin  and  a  subset  of  activated  T  cells  that 
produce Th2-type cytokines. The mAb Ber-H2 was conjugated with SAP giving an IT that specifically 
inhibits  protein  synthesis  in  Hodgkin-derived  cell  lines  with  IC50s  ranging  from  5  ×  10
−12  to  
5 ×  10
−14 M [46]. Because of transient hepatotoxicity observed in patients treated with Ber-H2-SAP, 
its  accumulation  in  rat  liver  cells  was  studied.  Adherent  cultured  non-parenchymal  cells,  mostly 
Kupffer cells, were found to accumulate this IT approximately 10 times more than parenchymal cells 
and to be 100-fold more sensitive to it [23]. In a SCID mouse model of human xenografted CD30
+ 
anaplastic large-cell lymphoma (ALCL) (the JB6 cell line), a 3-day treatment with non-toxic doses of 
Ber-H2-SAP (50% of LD50) induced complete remission in 80% of mice when treatment started 24 h 
after  tumor  transplantation.  In  contrast,  injection  of  the  IT  at  later  stages  of  tumor  growth  (mice 
bearing subcutaneous tumors of 40- to 60-mm
3 volume) significantly delayed tumor growth rate but 
induced complete remission in only 30% of mice. Thus, the efficacy of treatment with this IT appears 
to be related to tumor size [24]. Strong anti-tumor activity for Ber-H2-SAP was also observed in 
another SCID mouse model of ALCL (the D430B cell line). A dose of 0.1 mg/kg IT given 48 h after 
tumor transplantation caused complete remission in 4/6 mice and partial remission in 2/6 mice [25].  
Ber-H2-SAP  was  studied  in  a  phase  I/II  clinical  trial  in  four  patients  with  advanced,  refractory Toxins 2011, 3                               
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Hodgkin’s disease. Injection of this IT at a dose of 0.8 mg/kg (administered as two injections of 0.4 or 
as a single injection of 0.8) had an anti-tumor effect with only mild and transient hepatotoxicity. In all 
patients  there  was  a  rapid  (7  days  after  the  treatment)  reduction  in  tumor  mass,  and  3/4  patients 
achieved  partial  remission.  Two  patients  displayed  complete  relief  of  systemic  symptoms.  The 
responses lasted 6–10  weeks;  there was  no  growth at  new sites,  but  regrowth  occurred at  all the 
original sites except for the skin of one patient [35]. This study was extended to 12 patients with 
advanced Hodgkin’s disease (HD). A single i.v. injection of Ber-H2-SAP at doses 0.2–0.8 mg/kg 
induced  a  rapid  reduction  in  tumor  mass  in  about  60%  of  patients  with  partial  remission  in  
5/12 patients and MR in 2/12. This study is the first example of immunotherapy for HD and is the first 
case of cancer therapy with a type 1 RIP-containing IT leading to remission [36]. 
2.7. ITs Targeting CD38 
CD38  is  strongly  expressed  by  myeloma,  lymphoma  and  leukemia  cells.  A  limitation  to  the 
potential in vivo use of an anti-CD38 IT is the rather wide expression of CD38 antigen by several cell 
types. In a model of Ramos cells growing aggressively in SCID mice, an anti-CD38 IT (OKT10-SAP) 
was found to significantly prolong survival as compared with controls; but all the treated animals 
eventually succumbed to the disease [47]. 
The anti-CD38 IT IB4-SAP was studied in vitro in CD38
+ human cell lines (Raji, HBL6, L540 and 
CEM) and in CD38
+ neoplastic cells from a NHL patient. HBL6, L540 and Raji cells were highly 
sensitive to the IT with IC50 values ranging from 2 to 13 ×  10
−12 M and concentration causing 100% of 
protein synthesis inhibition (IC100) at 10
−10 M. CD38
+ neoplastic cells obtained from a NHL patient 
were completely eliminated with 10
−8 M IT. Colony-forming unit cell (CFU-c) rescue by bone marrow 
precursors was maintained after exposure to the IT [26]. 
2.8. ITs Targeting Costimulatory Antigens 
The most important regulatory signal for T-cell activation is the interaction between the antigen 
presenting cell (APC) surface molecules CD80 (B7-1) and CD86 (B7-2) and the T-cell molecules 
CD28  and  cytotoxic  T-lymphocyte  antigen-4  (CTLA-4).  These  molecules  are  also  present  on  the 
surface of many tumor cells and their expression at high levels often correlates with a poor prognosis. 
2.8.1. ITs Targeting CD80/CD86 
Strong expression of the CD80 antigen has been described on most Hodgkin and Reed-Sternberg 
cells independently of their histological subtype, whereas the CD86 antigen is particularly expressed 
by  the  histological  subtypes  showing  mixed  cellularity  or  nodular  sclerosis.  An  anti-CD80  IT,  
B7-24-SAP, exhibits strong cytotoxicity against the CD80
+ B-cell line Raji and the Reed-Sternberg 
cell lines HDLM2 and KM/H2 (IC50s < 10
−11 M). In clonogenic assays with Raji cells or KM/H2 cells, 
3 or 4 logs of killing, respectively, was observed. No cytotoxicity was found against B7-1
− epithelial 
or endothelial cell lines or against haematopoietic progenitor cells [27]. 
The mAbs, M24 (anti-CD80) and 1G10 (anti-CD86), after conjugation to SAP, showed specific 
cytotoxicity  for  the  CD80/CD86-expressing  cell  lines  Raji  and  L428.  These  ITs  inhibited  protein 
synthesis by target cells with IC50s ranging from 0.3 to 5.8 ×  10
−12 M. The anti-CD80 IT appeared to Toxins 2011, 3                               
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be 1 log more toxic to target cells than the anti-CD86 IT. These ITs at concentrations  10
−9 M showed 
some toxicity to CFU-c. However, the long term colture initiating cells (LTC-IC) assay did not detect 
any toxicity of these ITs even at the highest concentration tested (10
−7 M) [28]. 
2.8.2. ITs Targeting CD156 (CTLA-4) 
The CTLA-4 (CD152) co-stimulatory molecule, a homologue of CD28, plays an inhibitory role in 
regulating T cell responses by interacting with CD80/CD86 on APCs. CTLA-4 expression is induced 
on T cells upon activation, which is followed by its rapid internalization, and its membrane expression 
is restricted to activated T cells. ITs containing recombinant human-derived anti-CTLA-4 single-chain 
Fv  fragments  (scFv)  (namely  scFv-83  and  -40)  linked  to  SAP  induce  apoptosis  in  activated  
T lymphocytes. These ITs were able to specifically inhibit the mixed lymphocyte reaction between  
T-lymphocytes and dendritic cells, and that between T lymphocytes and an Epstein-Barr virus (EBV) 
positive lymphoblastoid B cell line. The most effective IT (83-SAP) tested on CD3/CD28-stimulated 
lymphocytes showed an IC50 of 8 ×  10
−11 M and a concentration causing apoptosis in 50% of cells 
(AC50) of 2 ×  10
−12 M
 [29,48]. No toxicity for hematopoietic precursors was reported. 83-SAP was 
tested in a model of tumor rejection consisting of C57BL/6 mice bearing a murine H.end endothelioma 
cell line derived from DBA/2 mice. The IT was injected at days 0, 1 and 2 at the dose of 4 μg. 
Lymphoid infiltration due to the presence of the tumor was markedly reduced, demonstrating that the 
IT was actually available and active in vivo [29]. Furthermore, 83-SAP at 10
−8 M causes apoptosis in 
more than 90% of neoplastic cells from an acute myeloid leukemia and its AC50 is in the 10
−11 M range 
[30]. 
2.9. ITs Containing Polyclonal Antibodies 
Despite their high selectivity, mAbs are frequently unable to mediate the killing of all the malignant 
cells.  Indeed,  differential  surface  marker  expression  and  variable  cell  surface  phenotypes  can  be 
observed in patients with the same type of hematological neoplasia. Polyclonal antibodies, which bind 
several  antigens  on  a  wide  range  of  cells,  offer  the  great  advantage  of  preventing  the  escape  of 
neoplastic clones during immunotherapy. Anti-thymocyte globulins (ATG) consist of a mixture of 
polyclonal antibodies that are specific for cell surface proteins, which include CD2, CD3, CD4, CD5, 
CD7, CD8, CD11a, CD19, CD20, CD25, CD28 and many others. ATG-SAP IT has a strong effect on 
lymphoma-  and  leukaemia-derived  cell  lines,  reducing  protein  synthesis  by  2–3  logs  (IC50  from  
5.3 ×  10
−11 to 1.3 ×  10
−10 M) with respect to unconjugated SAP (IC50 from 5.9 ×  10
−9 to 3.2 ×  10
−8 M). 
This IT causes cell killing without the need for complement dependent cytotoxicity or ADCC [31].  
2.10. Cocktails of Various Anti-Lymphocyte ITs 
Anti-CD7 and anti-CD38 F(ab’γ)2 BsAbs were used, alone or in combination, to deliver SAP to 
the cell surface of two human T-ALL cell lines (HSB-2 and HPB-ALL). Used alone against HSB-2 
cells, the anti-CD7 BsAb HB2 ×  DB7-18 increased SAP toxicity 435-fold and the anti-CD38 BsAb 
OKT10  ×  RabSap  increased  it  286-fold.  When  combined,  the  two  BsAbs  were  10-fold  more 
effective than the best single BsAb. On HPB-ALL cells, the CD7 BsAb HB2 ×  DB7-18 increased 
SAP  toxicity  only  eight-fold,  whereas  the  CD38  BsAb  OKT10  ×   RabSap  was  highly  effective, Toxins 2011, 3                               
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increasing SAP toxicity 80,000-fold. Interestingly, when both the anti-CD7BsAb HB2 ×  DB7-18 and 
anti-CD38 BsAb OKT10 ×  RabSap were used in combination, they were somewhat less effective 
than OKT10 ×  RabSap used alone. Indeed, the combination gave only a 50,000-fold increase in SAP 
toxicity compared with the 80,000-fold increase obtained with OKT10 ×  RabSap alone [14]. 
Treatment of SCID/CEM mice with a single IT containing the parental murine IgG1 anti-CD7 or 
anti-CD38 led to a delay in the development of leukemia, but 90% of animals treated with either IT 
developed  disseminated  leukemia  cell  growth.  The  combination  of  HB2-SAP  (anti-CD7)  plus  
OKT10-SAP (anti-CD38) administered in 3 ×  10 µg i.v. doses significantly increased survival time 
and the number of leukemia-free animals (60%) [49].  
SCID mice challenged with the CD19
+ CD38
+ human Burkitt’s lymphoma cell line Ramos treated 
with three daily injections of anti-CD19 BU12-SAP IT or of anti-CD38 OKT10-SAP IT starting at  
day  +7  showed  significantly  prolonged  survival.  When  both  ITs  were  used  in  combination  at 
equivalent doses, the therapeutic outcome was significantly improved over that obtained with single IT 
therapy, with 20% of animals surviving disease-free at 300 days [18]. Similar or even better results 
were achieved in the same Ramos/SCID mouse model
 with a mixture of three SAP ITs, anti-CD19,  
anti-CD22 and anti-CD38 [50]. 
3. ITs Targeting Solid Tumor Antigens 
Toxin-based conjugates have proven effective against lymphomas and leukemia, but the clinical 
results for solid tumor treatment have been quite disappointing. The principal reason is that ITs and 
other conjugates enter into solid tumors poorly and unevenly. Tight junctions between tumor cells, 
high interstitial pressure and heterogeneous blood supply are the main hurdles to conjugate penetration 
into the tumor mass. Thus, many strategies involving the use of recombinant antibody fragments, 
adjuvants (e.g., saponin) and photochemical internalization (PCI) have been investigated to improve 
the anti-tumor efficacy of conjugates [51]. The main results obtained in vitro and in animal models are 
summarized in Table 3. 
Table 3. SAP containing ITs or conjugates targeting solid tumors. 
  Antitumor Activity   
Carrier 
Target 
Antigen 
Tumor  In vitro IC50 (M) 
In vivo 
Ref. 
Schedule  Effects 
EGF  EGFR 
Sarcoma 
2.4 ×  10
−9 w/o 
saponin 
6.7 ×  10
−13 with 
saponin 
n.d.  n.d.  [52] 
Adenocarcinoma   
BALB/c-TSA mice 
4 ×  280 μg/kg 
71% TGR  
at 20 days 
[53] 
6 ￗ 5.6 μg/kg + 1670 μg/kg 
saponin 
94% TGR 
at 25 days 
[54] 
Cervical cancer   
SCID-cervical  
cancer mice 
6 ￗ 15 μg 
50–60% TGR  
at 30 days 
[55] Toxins 2011, 3                               
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Table 3. Cont. 
  Antitumor Activity 
Carrier 
Target 
Antigen 
Tumor  In vitro IC50 (M) 
In vivo 
Ref. 
Schedule  Effects 
FGF  FGFR 
Melanoma,  
teratocarcinoma and 
neuroblastoma 
10
−9~10
−11 
BALB/c-neuroblastoma 
mice 
4 ￗ 0.5 μg/kg 
CR 20%  [56] 
FGF-2  FGFR  Bladder cancer 
1.4 ×  10
−8~ 
1.3 × 10
−10 
n.d.  n.d.  [57] 
bFGF  FGFR  Prostatic carcinoma   
Athymic nude  
mice-DU145 
4 ￗ 5 μg/kg 
95% TGR 
at 38 days 
[58] 
ch25A11  CDCP1  Prostate carcinoma   
SCID CB17 mice 
3 ×  0.4 mg/kg 
66% TGR  
at 23 days 
[59] 
hj591  PSMA  Prostate carcinoma 
2 ×  10
−9~ 
1.4 × 10
−10 
Athymic nude  
mice-LNCaP 
4 ￗ 32 μg 
83–90% TGR 
at 49 days 
[60] 
Ep2  HMW-MAA  Melanoma  10
−10  n.d.  n.d.  [61] 
ML30  HSP65 
Leukaemic monocyte 
lymphoma 
10
−9  n.d.  n.d. 
[62] 
    Pancreatic carcinoma   
SCID-HPC-4 mice 
6 × 10
−7 M 
TR 15.9 IT 
TR 48.7 PBS 
48–127  gp54  Bladder tumor  10
−9  n.d.  n.d.  [63] 
I/F8 scFv 
ALCAM/ 
CD166 
Various  2.4~5 × 10
−9  n.d.  n.d.  [64] 
7E4B11  RPTPβ  Astrocytic tumor   
Athymic nude mice-
glioblastoma 
4 ￗ 30 μg 
73% TGD  [65] 
CR: complete remission; n.d.: not determined; TGR: tumor growth reduction; TGD: tumor growth delay;  
TR: tumor ratio (tumor volume day 6/tumor volume day 0). 
3.1. Conjugates Targeting Growth Factor Receptors 
It  is  well  known  that  growth  factors  play  an  important  role  in  normal  cell  proliferation  by 
stimulating growth factor receptors located on the cell surface. Tumor cells express high levels of 
growth factor receptors that theoretically can serve as therapeutic targets in cancer treatment. 
3.1.1. Conjugates Targeting EGFR 
The epidermal growth factor receptor (EGFR) is overexpressed in many different types of solid 
tumors and is associated with metastasis and poor prognosis. 
Two of the main problems associated with administering EGFR-targeted toxins in tumor therapy 
are severe systemic side effects and low transfer of the toxins into the cytosol after binding to the 
tumor cell surface. 
Members  of  the  HER/erbB  receptor  family  seem  to  be  involved  in  several  human  cancers. 
Overexpression of these receptors has been found in many types of epithelial, mesenchymal and neural Toxins 2011, 3                               
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cancer,  and  it  correlates  with  tumor  progression  and  with  reduced  patient  survival  [66]. 
Rhabdomyosarcoma  cells  (RD/18)  were  treated  with  an  indirect  IT  consisting  of  a  murine  mAb 
recognizing EGF-R (clone 528) followed by a secondary F(ab’)2 antimouse immunoglobulin linked to 
SAP.  This  IT  induced  apoptosis  and  significantly  inhibited  cell  growth  and  protein  synthesis  
(IC50 9.5 ×  10
−10 M) [67]. 
Recombinant SAP [68] has been linked to EGF both directly (SE) and via an adapter (SA2E). The 
adapter is designed to improve cytosolic uptake and to retain the toxin inside the cytosol. Heisler et al. 
evaluated the toxicity of SA2E on an EGFR
+ cell line (HER14 cells derived from mouse embryo  
NIH-3T3 cells transfected with human EGFR). Pre-incubation with an adjuvant (saponin) enhanced 
the cytotoxicity of SA2E more than 3 logs (from an IC50 of 2.4 ×  10
−9 to 6.7 ×  10
−13 M) [52]. The 
efficacy  with  which  SE  and  SAE2  inhibit  tumor  growth  was  evaluated  in  BALB/c  mice  bearing 
adenocarcinoma TSA-EGFR
+ cells. The lethal dose for mice was three times lower for SA2E than for 
SE. Mice were injected with 1.25 ×  10
5 cells and 5 μg (280 μg/kg) of conjugate was injected s.c. 4 h 
later in the immediate vicinity (day 0). Further doses were applied on days 3, 6 and 11. The average 
tumor volume exceeded 5 mm
3 on days 10, 11, 14 and
 18 for SAP-treated, untreated, SE-treated and 
SA2E-treated mice, respectively. After 20 days of treatment, SE only reduced the average weight of 
induced tumors by 33%, whereas SA2E-treated mice exhibited 71% tumor reduction. Additionally, 
severe side effects like hyperalgesia, alopecia and death were drastically reduced in SA2E-treated 
animals  [53].  Furthermore,  6  s.c.  injections  of  30  μg  saponin  and  0.1  μg  SA2E  (equivalent  to  
5.6 μg/kg) reduced the mean tumor volume after 25 days, by a remarkable 94% compared to controls. 
Although saponin alone had no effect on tumor growth, SA2E alone reduced the mean tumor volume 
slightly by 42% compared to the controls. Surprisingly, in the i.p. injection saponin/SA2E and SA2E 
alone did not inhibit tumor growth [54]. In SCID beige mice bearing freshly isolated cervical cancer 
cells, treatment with 6 s.c. injections of 5 and 10 μg of SA2E decelerated tumor growth by about  
20–30%, whereas treatment with 15 μg reduced tumor growth by 50–60% compared to the control 
group. However, the antitumor effect of SA2E was restricted to the treatment period, and after the 
SA2E applications were discontinued the tumors showed rapid outgrowth [55]. 
Weyergang  et  al.  demonstrated  that  a  conjugate  based  on  EGF  linked  to  SAP  is  efficiently 
endocytosed in two EGFR
+ cell lines (NuTu-19 from an epithelial ovarian tumor and A-431 from a 
skin carcinoma). Moreover, the photochemical internalization (PCI) of EGF-SAP improved both the 
efficacy and specificity of the conjugate. Indeed, PCI enhanced the efficacy of EGF-SAP by about 
1000  times  in  NuTu-19  cells.  At  a  dose  where  the  photochemical  treatment  reduced  viability  by 
approximately 50%, the dose causing death in 95% of population (LD95) for PCI of SAP was about 
10
−9 M, whereas the LD95 for PCI of the conjugate was about 10
−12 M. PCI of EGF-SAP was several 
hundred-fold less efficient at enhancing cytotoxicity in non-target cells than in target cells [69]. PCI 
has been used to deliver an IT consisting of the anti-EGFR mAb cetuximab linked to SAP into various 
types of EGFR
+ carcinoma cell lines (colorectal, prostate, epidermoid). The PCI treatment enhanced 
the cytotoxicity of the IT in a synergistic manner. Indeed, PCI improved the IT toxicity approximately 
10–20 times [70]. Toxins 2011, 3                               
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3.1.2. Conjugates Targeting FGFR 
Fibroblast growth factor receptors (FGFRs) are a family of at least 12 different proteins. Many solid 
tumors express receptors binding basic FGF (also named FGF-2 or bFGF). A conjugate containing 
basic  FGF  linked  to  SAP  was  found  to  be  toxic  to  FGFR
+  cell  lines  (human  melanoma, 
teratocarcinoma  and  neuroblastoma).  The  conjugate  showed  IC50s  ranging  from  10
−11  to  10
−9  M, 
whereas  unconjugated  SAP  had  IC50  values  >10
−7  M.  BALB/c  mice  bearing  human  melanoma, 
teratocarcinoma or neuroblastoma cells  were treated  with  4 i.v.  injections  of 0.5  µg/kg  conjugate 
beginning on day +5. Significant tumor inhibition was seen on day 35 for each of the tumor types 
examined and complete tumor regression was observed in 20% of the neuroblastoma xenografts. No 
cumulative toxicity was observed  [56]. The same conjugate was  also  evaluated in  C75BL/6  mice 
bearing B16-F10 cells (murine melanoma). The conjugate increased survival time, inhibited tumor 
growth and decreased metastasis [71]. 
The chemical and the recombinant FGF-2-SAP conjugates have potent cytotoxicity in malignant 
bladder cell lines with IC50s ranging from 1.3 ×  10
−10 to 1.4 ×  10
−8 M, whereas cells derived from 
normal fetal bladder were found to be less sensitive to FGF-2-SAP (IC50 > 10
−7 M) [57]. 
The antitumor activity of recombinant bFGF-SAP was examined in athymic nude mice bearing a 
prostatic carcinoma cell line (DU145). The conjugate (4 ×  5 µg/kg) was administrated by i.v. injection, 
intraperitoneal injection, or local or distal s.c. injection beginning 5 days after s.c. tumor implantation. 
No significant difference was observed between the groups receiving the conjugate via i.v. injection 
versus intraperitoneal injection out to day 38. However, tumors receiving local s.c. injections were 
significantly  smaller.  Moreover,  the  conjugate  induced  dramatic  reduction  of  large  (450  mm
3) 
established tumors out to 20 days after treatment in 2 animals who received 50 µg/kg bFGF-SAP on 
day +75 and +85 after tumor injection [58].  
3.2. Conjugates Targeting the Transferrin Receptor 
The  transferrin  receptor  (TfR)  is  expressed  on  all  normal  tissue  cells,  but  it  is  chosen  as  an 
immunotherapy  target  for  gliomas  and  other  tumor  cells  because  of  the  high  iron  requirement  of 
rapidly  proliferating  neoplasms.  ITs  targeting  the  TfR  were  hypothesized  to  possess  sufficient 
specificity to eliminate neoplastic cells in the central nervous system or in other compartments where 
the  delivery  of  ITs  to  a  tumor  does  not  require  transvascular  transport.  Two  different  conceptual 
approaches have been designed to target TfR on cancer cells. Conjugates have been made using the 
plasma protein transferrin as a carrier, and alternatively, anti-TfR mAbs have been used. Both types of 
proteins can be used to deliver the RIP to target cells; however, Tf-based conjugates have two major 
disadvantages  with  respect  to  mAb-based  conjugates  as  they  are  strongly  influenced  by  both  the 
presence of free transferrin and the saturation state of iron [72]. 
A transferrin-SAP conjugate was found to be internalized via binding with TfR. The conjugate 
inhibited  K562  (human  erythroleukaemia)  cell  proliferation  and,  in  a  clonogenic  assay,  markedly 
inhibited K562 colony formation (close to 100% at 10
−9 M) [73]. Conjugation of IgG3-avidin specific 
for the human-transferrin receptor (anti-hTfR IgG3-Av) with biotinylated SAP was found to enhance 
the cytotoxic effects of SAP in TfR bearing IM-9 (EBV-transformed lymphoblastoid cell line) and Toxins 2011, 3                               
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U266  (a  lymphoblast  cell  line)  cells.  Indeed,  protein  synthesis  was  strongly  reduced  after  48  h  
of 10
−9 M IT treatment in both cell lines [74]. 
Recently, a transferrin-SAP conjugate has been assayed on two glioblastoma multiforme cell lines, 
GL15 and U87. The conjugate resulted active on both cell lines but after 72 h of incubation with  
10
−9 M transferrin-SAP less than 50% of tumor cells was killed [75]. 
3.3. ITs Targeting Prostatic Antigens 
Prostate cancer is a good target for antibody-based therapy because the non-vital function of the 
prostate allows extending the spectrum of target molecules to tissue-specific markers, not restricted to 
tumor cells. Moreover, the usually small size metastases can be easily reached and destroyed by ITs. 
Ku70/80 protein is expressed in the nucleus of all cells, but its plasma membrane localization is 
restricted to tumor cell lines of various lineages. Carcinoma cell lines, with varying surface expression 
of Ku70/80, were pre-treated with 1 ×  10
−8 M of INCA-X IgG, an anti-Ku70/80 antibody, and then 
incubated with a SAP-anti-human IgG antibody (Hum-ZAP). The inhibition of proliferation induced 
by INCA-X/Hum-ZAP ranged from very strong (92% on the prostate carcinoma PC-3) to low (30% on 
the  colorectal  carcinoma  LS174  T),  whereas  no  effect  was  seen  on  the  Ku70/80-negative  breast 
carcinoma cell line SK-BR-3 [76]. 
Tomoregulin  is  a  type  1  transmembrane  protein  with  a  short  cytoplasmic  tail.  This  protein  is 
selectively expressed in the prostate and brain but it is not expressed in other normal tissues. 2H8, an 
anti-Tomoregulin murine mAb, was coupled to SAP through a mAb-ZAP secondary antibody (goat 
antimouse IgG antibody linked to SAP) in indirect IT assays. The SAP-based 2H8 IT was found to 
specifically  bind  to  Tomoregulin-positive  cells  and  induce  a  50%  reduction  of  viability  at  the 
concentration of 1.6 ×  10
−10 M after 72 h, whereas Tomoregulin-negative cells remained unaffected [77]. 
CUB  domain-containing  protein  1  (CDCP1)  is  widely  expressed  in  tumors,  including  prostate 
cancer, and it is recognized by the chimaeric mAb 25A11 (ch25A11). An IT containing SAP coupled 
to  ch25A11 was  evaluated  in  vivo in  SCID CB17 mice bearing prostate carcinoma cells.  The  IT  
(3 ×  0.4 mg/kg) administered i.v. inhibited tumor growth by approximately 66% at day 18, 67% at day 
22 and 63% at day 23, whereas no inhibition was observed with s.c. injection of the IT at the same 
dose. However, both i.v. and s.c. IT administration were found to inhibit tumor metastasis, suggesting 
that although s.c.  IT may  not  have sufficient  bioavailability to  inhibit  primary tumor  growth,  the 
inhibition of metastasis may be a direct result of tumor cell killing in the circulation [59]. 
PSMA is a prostate-specific cell surface marker of prostate cancer. The antitumor activity of the 
anti-PMSA humanized biotinylated mAb hJ591 linked to streptavidin SAP (SAZAP) was evaluated in 
prostate derived cell lines: LNCaP, CWR22Rv1 (both PMSA
+) and PC-3 (PMSA
−). The IC50 of this IT 
was  1.4  ×  10
−10  M,  2 ×  10
−9  M  and  more  than  10
−7  M  in  LNCaP,  CWR22Rv1  and  PC-3  cells, 
respectively. After 72 h of treatment with this IT, the percentage of apoptotic cells was 60% and 40% 
in LNCaP and CWR22Rv1 cells, respectively, compared to about 5% in PC-3 cells. The conjugate also 
had anticancer activity in an LNCaP xenograft model in athymic nude mice. The administration of 
hJ591-SAZAP  (4  ×  32  μg  doses  weekly)  was  found  to  inhibit  tumor  growth  in  IT-treated  mice 
compared to control groups. Indeed, after 7 weeks of treatment, the tumor volume in untreated mice 
was 5- to 6-fold greater than in IT-treated mice. In addition, serum PSA (prostate-specific antigen) 
values were 0.39 ±  1.04 ng/mL and 71 ±  52.85 ng/mL for treated and untreated groups, respectively [60]. Toxins 2011, 3                               
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3.4. ITs Targeting Other Antigens on Solid Cancers 
Selective elimination of multidrug resistance  (MDR)-positive cells  (also  called  LoVo/Dx colon 
carcinoma cells) was obtained using the mAb MRK16, which recognizes P-glycoprotein 170, and a 
sheep anti-mouse immunoglobulin conjugated to SAP. When the IT was used at concentrations of  
10
−8 and 10
−7 M, the inhibition of protein synthesis was 73% and 87%, respectively. MRK16 followed 
by the indirect IT was found to eliminate 99% of MDR cells from a bone marrow suspension [78]. 
High-molecular-weight  melanoma-associated  antigen  (HMW-MAA)  is  expressed  on  a  large 
majority of melanomas but not on most normal or other neoplastic tissues. The mAb Ep2, recognizing 
an epitope of HMW-MAA, was conjugated to SAP. Ep2-SAP IT efficiently killed antigen expressing 
cells with an IC50 of approximately 10
−10 M [61]. 
Heat Shock Proteins (HSP) represents a family of highly conserved molecules that under stress 
conditions play an important physiological role in folding and unfolding of proteins. Moreover HSPs 
have  been  described  as  tumor-associated  antigens;  they  are  constitutively  overexpressed  in  the 
intracellular compartment and sometimes on the surface of tumor cells. The cytotoxic effect of an  
anti-HSP65  mAb (ML30) on untreated  and heat-treated H9  cells  (CD4
+ lymphoma  cell line)  was 
evaluated with an indirect  IT (ML30 + anti-mouse IgG antibody linked to SAP). The IT showed 
marked cytotoxicity against heat-stressed H9 cells at 10
−11 and 10
−13 M, whereas normal H9 cells were  
spared [79]. Proliferation of the U937 cell line (a monocytic cell line that constitutively expresses high 
levels of membrane HSP65) was evaluated using indirect IT or ML30-SAP direct IT. The inhibition of 
cell proliferation for both ITs was 100% at 10
−7 M with an IC50 of 10
−9 M. After 6 treatments with  
10
−7 M IT in SCID mice bearing HPC-4 cells (human pancreatic carcinoma), the treatment ratio (tumor 
volume on day 6/tumor volume on day 0) was significantly lower in the IT-treated group than in the 
control  group  (15.9  for  the  IT  group;  48.7,  44.8,  43.2  for  the  PBS,  SAP  and  ML30  groups, 
respectively) [62]. 
The 48-127 mAb recognizes a glycoprotein (gp54) expressed on all human bladder tumors and on 
normal urothelium but not on the luminal surface of normal urothelial umbrella cells. The antigen gp54 
is expressed also in non proliferating tumor cells. Thus, ITs specific for this antigen will ensure the 
killing of resting cells, which are usually spared by conventional chemotherapy. A 48-127-SAP IT was 
toxic to the T24 target cell line derived from bladder carcinoma, with IC50s at nM concentrations after 
2 h of incubation followed by 72 h in serum-free RPMI. The inhibition of protein synthesis in T24 
cells required 2 h of contact with the IT to ensure optimal binding and endocytosis [63]. 
Carcinoembryonic  antigen-related  cell  adhesion  molecule  6  (CEACAM6)  is  a 
glycosylphosphatidylinositol-linked cell surface protein that is overexpressed in a variety of human 
cancers,  including  the  majority  of  pancreatic  adenocarcinomas.  Exposure  of  pancreatic  ductal 
adenocarcinoma  cells  (BxPC3)  to  anti-CEACAM6  antibody  (By114)  followed  by  secondary  
SAP-conjugated immunoglobulin was found to induce marked cytotoxicity. In athymic nude mice 
bearing BxPC3 cells, the administration of By114 followed by IgG-SAP by two tail vein injections 
separated by two weeks caused a marked reduction in mean tumor volume after 6 weeks and in some 
cases tumor regression occurred [80]. 
Activated leukocyte cell adhesion molecule (ALCAM/CD166) is a member of the immunoglobulin 
gene superfamily. It is expressed on a number of carcinoma cells and cell lines and in the invasive Toxins 2011, 3                               
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cells of melanocytic skin lesions where its expression correlates with tumor progression. The toxicity 
of an IT containing I/F8 scFv linked to SAP was assayed on both human and murine ALCAM/CD166
+ 
cell lines, in which it was at least 100-fold higher than that of free SAP with IC50s ranging from 2.41 to 
5.06 ×  10
−9 M [64]. 
Receptor protein tyrosine phosphatase β (RPTPβ) is overexpressed primarily in astrocytic tumors. It 
is known to facilitate tumor cell adhesion and migration through interactions with the extracellular 
matrix. RPTPβ-7E4B11 and RPTPβ-7A9B5 antibodies were conjugated to SAP and evaluated in vitro 
for their ability to kill glioma cells. These ITs effectively killed tumor cells, reducing their viability by 
about  50%  compared to vehicle-treated cells.  The  in  vivo efficacy of 7E4B11  IT was  assayed  in 
athymic nude mice bearing glioblastoma cells. At 15 and 30 μg/dose (twice a week for two weeks), the 
IT  produced  25%  and  73%  tumor  growth  delays,  respectively.  All  tumors  reached  the  end-point 
volume by day 44. The median time to end point of PBS-treated mice was 18.6 days, whereas the IT 
(30 μg/dose) treated mice had a time to end-point of 32.1 days [65].  
Overexpression  of  the  enzyme  human  aspartyl  (asparaginyl)  β-hydroxylase  (HAAH)  has  been 
detected in a variety of cancers including lung, liver, colon, pancreas, prostate, ovary, bile duct and 
breast cancer. It has been proposed that upon cellular transformation, HAAH is overexpressed and 
translocated  to  the  cell  surface.  The  anti  HAAH  scFv  6–22  was  used  to  deliver  goat-anti-human  
IgG-SAP  conjugates  (H-Z)  into  FOCUS  cells  (a  liver  tumor  cell  line)  (1  ×  10
−8  M  of  6–22  and  
2.2 ×  10
−8 M of H-Z). The viability of the 6–22/H-Z treated cells was lower by about 30% after 3 days 
of incubation [81]. 
Endosialin/CD248/tumor endothelial marker 1 is expressed in stromal cells, endothelial cells and 
pericytes in various tumors. The endosialin-positive Ewing’s sarcoma cell line A-673 was exposed to 
anti-endosialin mAb followed by anti-human IgG conjugated to SAP. The cells were sensitive to the 
endosialin toxin conjugate with an IC50 of approximately 10
−12 M [82]. 
The cell cycle-associated overexpression of transcobalamin receptor (CD320) in many cancer cells 
provides a suitable target for delivering chemotherapeutic drugs  and cytotoxic molecules. Various  
anti-CD320 mAbs were used to deliver IgG-SAP into human colon adenocarcinoma and epidermoid 
carcinoma  cell  lines.  The  IC50  was  in  the  0.625  to  2.5  ×  10
−9  M  range  for  the  primary  mAb 
concentration [83]. 
TEM8 is an integrin-like cell surface protein that is upregulated on tumor blood vessels and it is a 
potential vascular target for cancer therapy. 293/FlagT8 cells (kidney epithelial cells transformed with 
adenovirus) are recognized by the anti-TEM8 mAb AF334. Cell viability after treatment with AF334 
mAb along with 5 ×  10
−9 M or 1 ×  10
−8 M of SAP-conjugated anti-mouse antibody was almost 40% 
and 30%, respectively [84]. 
4. Conclusions 
The type 1 RIP saporin has been utilized to construct conjugates and ITs against numerous targets 
with interesting results in many pre-clinical studies (Tables 1 and 3). Great efficacy has been reported 
frequently  in  many  models  of  hematological  tumors.  In  several  experiments  conducted  on  mice, 
treatment with SAP-containing ITs resulted in the elimination of transplanted tumors. 
The results achieved in experiments on solid tumors have been less remarkable than those obtained 
in  hematological  malignancies,  but  they  have  often  been  better  than  those  reported  for  other Toxins 2011, 3                               
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experimental cancer drugs. 
Clinical trials with SAP-containing immunotoxins, whose results are summarized in Table 2, show 
the  efficacy  of  these  molecules  and  their  potential  for  application  in  lymphoma  therapy.  Taken 
together, the studies summarized in this review indicate that saporin-based immunotoxins are almost 
always extremely powerful in vitro and maintain good anti-tumor efficacy in vivo. This, at least in part, 
is due to the intrinsic characteristics of saporin, which is a very stable enzyme. Indeed this protein is 
very  resistant  to  chemical  modifications  and  conjugation  and  to  blood  and  endosomal  proteases. 
Moreover, saporin appears to have a wide range of possible intracellular substrates, thus triggering 
multiple cell death pathways [85]. This multifaceted cytotoxic mechanism renders the selection of 
RIP-resistant mutants impossible. 
Clinical  results  have  demonstrated  the  efficacy  of  immunotoxins  in  cancer  patients  that  are 
refractory  to  traditional  modalities  of  treatment:  surgery,  radiation  therapy,  and  chemotherapy. 
However so far, the use of immunotoxins in cancer therapy has not completely fulfilled the hopes. 
Indeed, immunotoxins have multiple problems, mainly: formation of antibodies against the carrier and 
the RIP, capillary leak syndrome and hepatotoxicity. Modern technologies should permit to circumvent 
or reduce some of these problems. The use of humanized antibodies can abolish the immune response 
against the carrier; on the other hand the consequences of the response against the RIP could be easily 
overcome with cycles of therapy based on the rotation of immunologically different RIPs. Moreover 
the use of antibody fragments leads to smaller immunotoxins with better penetration in solid tumour 
tissues than immunotoxins constructed with whole antibodies. Recently many clinical trials have been 
conducted, and several are ongoing, with immunotoxins, prevalently constructed with deglycosylated 
A  chain  of  ricin,  truncated  diphtheria  toxin  or  Pseudomonas  exotoxin  A,  but  not  with  saporin. 
Nevertheless, saporin would have many advantages with respect to these toxins, in terms of stability 
and efficacy, as described above and thanks to the lacking of the natural immunization often present 
against bacterial toxins. 
Ehrlich’s idea of a “magic bullet” postulated one century ago has not been completely realized to 
date. Nevertheless, over the last two decades, advances in genetic engineering and in receptor biology 
have led to many improvements in carriers, creating potential for saporin- and other RIP-containing 
conjugates to be widely used in cancer therapy. 
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